SCHEMBL7984549

SCHEMBL7984549

CNC(=O)c1cc(OC)ccc1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 2/20 0.62
MTNR1A P48039 1/20 0.55
P2RX7 Q99572 5/20 0.54
P2RY12 Q9H244 1/20 0.54
PLK1 P53350 1/20 0.53
MAPT P10636 2/20 0.52
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 3/20 0.51
GAA P10253 3/20 0.51
HPGD P15428 3/20 0.51
HSD17B10 Q99714 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
GLA P06280 1/20 0.51
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
POLB P06746 1/20 0.49
ANO1 Q5XXA6 1/20 0.48
PKM P14618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11037222 0.86 TYK2 (0.62) TYK2MTNR1APLK1MAPTKDM4E
SCHEMBL1180024 0.82 KDM4E (0.60) TYK2P2RX7P2RY12MAPTKDM4E
SCHEMBL27619952 0.81 TYK2 (0.57) TYK2P2RX7P2RY12MAPTKDM4E
SCHEMBL27639068 0.81 TYK2 (0.57) TYK2P2RX7P2RY12MAPTKDM4E
SCHEMBL17414607 0.81 P2RX1 (0.57) MTNR1APLK1MAPTKDM4EALDH1A1
SCHEMBL8360010 0.81 MTNR1A (0.56) MTNR1APLK1MAPTKDM4EALDH1A1
SCHEMBL1363543 0.80 TYK2 (0.55) TYK2P2RX7P2RY12MAPTKDM4E
SCHEMBL696853 0.80 ALDH1A1 (0.59) TYK2P2RX7P2RY12MAPTKDM4E
SCHEMBL4261329 0.80 SMN1; SMN2 (0.59) TYK2MAPTKDM4EALDH1A1HPGD
SCHEMBL21668146 0.79 TYK2 (0.51) TYK2P2RX7P2RY12MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4605392-A1 METHODS FOR TREATING CANCER Antares Therapeutics, Inc. (US) 2025-08-27 EP disclosed
WO-2024086809-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. (US) 2024-04-25 WO disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 TYK2 3614/4885MTNR1A 885/4885P2RX7 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.